Search

Displaying results 3521 - 3530 of 6076 in total
  1. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  2. Drug

    Heparan-N-sulfatase (human, recombinant)

    go.drugbank.com/drugs/DB18483
    Investigational

    Recombinant human heparan-N-sulfatase (rhHNS) is under investigation for the treatment mucopolysaccharidosis type IIIA.

  3. Drug

    Fluocortin

    go.drugbank.com/drugs/DB13223
    Experimental

    Fluocortin has been studied as a corticosteroid for treatment of dermatitis and eczema Spain [A174817].

  4. Drug

    Ulinastatin

    go.drugbank.com/drugs/DB12038
    Investigational

    Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.

  5. Drug

    Atopaxar

    go.drugbank.com/drugs/DB12046
    Investigational

    Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome.

  6. Drug

    AZD-7762

    go.drugbank.com/drugs/DB12242
    Investigational

    AZD7762 has been investigated for the treatment of Cancer, Solid Tumors, and Advanced Solid Malignancies.

  7. Drug

    Utomilumab

    go.drugbank.com/drugs/DB15113
    Investigational

    Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

  8. Drug

    Dapivirine

    go.drugbank.com/drugs/DB08639
    Investigational

    Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.

  9. Drug

    Epirizole

    go.drugbank.com/drugs/DB08991
    Experimental

    Epirizole is an oral nonsteroidal anti-inflammatory drug (NSAID) used for muscle and joint pain.

  10. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System